CTSO (cytosorbents.com) צמיחת רווח נקי למניה השנה

The proportional growth of EPS compared to last year demonstrates the results of Cytosorbents (CTSO) partnerships with hospitals and scientific centers for blood purification, where -72.60 shows the level of this metric. The unique CytoSorb system ensures leadership in sepsis treatment by removing excess cytokines. The company is currently developing a mature product line, expanding its clinical base and penetrating new medical niches.

The efficiency of Cytosorbents (CTSO) expansion into new intensive care niches is reflected in the year-over-year EPS growth rate dynamics. This indicator measures the annual change in earnings per share, neutralizing the impact of infrequent financial reports through daily recalculation. Such a methodology allows for the filtering of random market noise from genuine fundamental progress. The steady rise of this metric confirms the commercial success of the CytoSorb technology, while the positive trend demonstrates the high resilience of the business model.